Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polymerized Dermatophagoides pteronyssinus allergoid
- Development stage
- Phase 2
- Lead developer
- Laboratorios Diater
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Polymerized Dermatophagoides pteronyssinus allergoid is an allergen immunotherapy (AIT) product developed by Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas, S.A. It consists of an allergenic extract derived from the house dust mite *Dermatophagoides pteronyssinus* that has been chemically modified through polymerization with glutaraldehyde. This polymerization process is intended to reduce the allergenicity (IgE-binding capacity) of the native extract, thereby enhancing safety by minimizing the risk of systemic allergic reactions, while preserving its immunogenicity to induce a protective immune response. The drug is primarily indicated for the treatment of allergic rhinoconjunctivitis and mild-to-moderate allergic asthma associated with house dust mite sensitization. It is administered via the intradermal route and has been investigated in Phase 2 clinical trials to confirm the maximum non-reactive dose and evaluate safety in sensitized adults.
- Other names
- polymerized D. pteronyssinusglutaraldehyde-polymerized Dermatophagoides pteronyssinus extract
02
Targets
Der p 1 (Dermatophagoides pteronyssinus allergen 1)Der p 2 (Dermatophagoides pteronyssinus allergen 2)
Beyond the preview
Go deeper on polymerized Dermatophagoides pteronyssinus allergoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polymerized Dermatophagoides pteronyssinus allergoid.